SLDB
NASDAQ · Biotechnology
Solid Biosciences Inc
$8.58
-0.13 (-1.49%)
Open$8.59
Previous Close$8.71
Day High$8.93
Day Low$8.52
52W High$11.45
52W Low$3.79
Volume—
Avg Volume963.9K
Market Cap824.52M
P/E Ratio—
EPS$-1.95
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
+27.0% upside
Current
$8.58
$8.58
Target
$10.90
$10.90
$9.47
$10.90 avg
$14.24
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 294.33M | 265.12M | 296.42M |
| Net Income | 32.12M | 33.11M | 29.81M |
| Profit Margin | 10.9% | 12.5% | 10.1% |
| EBITDA | 56.98M | 46.74M | 49.34M |
| Free Cash Flow | 40.15M | 38.44M | 35.75M |
| Rev Growth | +16.9% | -8.0% | -9.5% |
| Debt/Equity | 0.34 | 0.27 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |